about
Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or TulathromycinCorrection: Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or TulathromycinPharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.Performance of the 808-nm diode laser on equine upper airway tissue is enhanced by intravenous administration of indocyanine green.Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.Pharmacologic considerations for opiate analgesic and nonsteroidal anti-inflammatory drugs.Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseasesPharmacologic management in veterinary behavioral medicine.Antimicrobial therapy for gastrointestinal diseases.ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance.Factors influencing the gastric residence of dosage forms in dogs.An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals.Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?Ciprofloxacin Pharmacokinetics in Clinical Canine Patients.Pharmacokinetics of intravenous clindamycin phosphate in captive Bennett's wallabies (Macropus rufogriseus).Opinions of clinical veterinarians at a US veterinary teaching hospital regarding antimicrobial use and antimicrobial-resistant infections.Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases.Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis).Population pharmacokinetics of enrofloxacin in purple sea stars (Pisaster ochraceus) following an intracoelomic injection or extended immersion.Antiulcer therapy.Workshop report: the 2012 antimicrobial agents in veterinary medicine: exploring the consequences of antimicrobial drug use: a 3-D approach.Principles of analgesic drug therapy.Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous AdministrationEfficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats.Pharmacokinetics of florfenicol in serum and synovial fluid after regional intravenous perfusion in the distal portion of the hind limb of adult cows.New interpretive criteria for danofloxacin antibacterial susceptibility testing against Mannheimia haemolytica and Pasteurella multocida associated with bovine respiratory disease.Pharmacokinetics of an extended-release formulation of eprinomectin in healthy adult alpacas and its use in alpacas confirmed with mange.POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND ITS METABOLITE CIPROFLOXACIN IN THE GREEN SEA URCHIN (STRONGYLOCENTROTUS DROEBACHIENSIS) FOLLOWING INTRACOELOMIC AND IMMERSION ADMINISTRATION.Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs.Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats.Pharmacokinetics of minocycline in domestic cats.PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS).Antibacterial drug therapy. Focus on new drugs.Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy.Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs.Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs.
P50
Q27322047-D5496C69-ED90-487C-B2CF-0E9C17F4C4C0Q28552486-5D378C9E-3223-46F3-932C-9F6E3E7EA48CQ30803863-3A760FAD-4612-4AC1-A377-76B8B8C56E33Q33304671-A5255275-6E98-4328-A793-C1C7376D3CFCQ33976624-2EE41183-6311-4F53-8668-37F53AFA238AQ33982531-C66B3376-723C-4B77-B2EC-CE414C775FFBQ33995595-B2A5B1E3-649A-4DA8-B294-6339B0596142Q35101281-1FD2656C-9055-4B45-ADBD-A24DD452E4FAQ35109916-FD0D4048-FB80-42FB-96D0-47B484B44FCAQ35637002-B78285C2-7F6F-4EBF-A11D-EB85B9232D11Q36975171-6E0666C6-1AA1-45B0-AB4A-21BC1A6ADB37Q37228672-B8201059-D60B-4011-9959-AA58AF7E086FQ37309513-0E0C23D5-1F71-416D-AEFF-CB9420310B56Q37982099-EF7F72F0-AF80-48BC-AFD8-E86DDE25A508Q38644145-CD793E14-F1AD-48D9-9ACA-044566ECF6E3Q38751910-3F9D6C54-3E19-43A4-8393-C07A056635B3Q38958343-D80CDC06-4567-4E66-8D9C-6DD494489CFFQ38968445-380C95BB-00CB-48E9-ACAA-5559A2D6323AQ39014473-E0E363D0-09E0-4FE9-BA91-EB3B3EB30EAFQ39018653-FF7C0E51-F544-42EE-85B8-2D84D17174E3Q39224547-6E8909F7-C147-4B49-A54F-6575E79F2C07Q39232391-4FA7D166-A165-40E3-A3EE-7018564171E7Q39261097-BA985778-FE96-4CDA-B65A-DCBE8876BDB3Q39456105-BD2E44DE-F600-4B6C-8B0B-AC17FB1AC475Q39593613-9D4CF76B-8FE6-4550-93E1-FCBF3ACAAA46Q39785273-07FAA5F3-3D4C-409B-A6B9-C169A16A8CBEQ39855437-C488C1AC-1336-4DE9-93CB-16FC0A9EDC1EQ40390511-0A5313BD-7C19-4D82-B166-D4528D7EC862Q40536307-C8A91F8F-FE11-45DF-A93F-D638B5D516EAQ40742793-7E082F38-32BE-401D-878F-649720C6B982Q41001936-47341C70-0F5D-43D4-8785-D2D022F32EDBQ41060016-8C7C1D9F-B7AE-405A-8A9A-752F61F0B453Q41104042-722AB75D-A730-427E-AFC5-4934C4E058CFQ41173683-720B0D27-A4B9-456F-9EBB-2FB81F1624E1Q41747308-BACFDEF0-7759-4B85-81BB-5BC54F666D05Q41827471-E34FF697-654F-4186-ABC4-8C57A2472D97Q41877197-0735745B-1665-4316-8F08-CD720A976EADQ41986693-173E7BFC-0BBC-40F9-8459-10F4B58263A0Q42739321-E1153425-3EF4-4CDD-B1A0-64540F744E4FQ42789931-E64ADB96-C504-4049-A049-037357EFD3FD
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7591-7898
@en
name
Mark Papich
@ast
Mark Papich
@en
Mark Papich
@es
Mark Papich
@nl
type
label
Mark Papich
@ast
Mark Papich
@en
Mark Papich
@es
Mark Papich
@nl
prefLabel
Mark Papich
@ast
Mark Papich
@en
Mark Papich
@es
Mark Papich
@nl
P106
P21
P31
P496
0000-0002-7591-7898